ImmunityBio Inc. Securities Litigation Settlement
This settlement is closed to new claims — the deadline was July 7, 2025. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
Lead Plaintiff alleges that ImmunityBio, Inc. and its executives made false or misleading statements regarding the company's securities during the class period. The defendants have agreed to settle the litigation for $10,500,000 in cash without admitting wrongdoing.
Do you qualify?
Anyone who purchased or acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between March 10, 2021, and May 10, 2023, inclusive.
How to file
Submit a Proof of Claim and Release Form to the settlement claims administrator by July 7, 2025. The form must include documentation proving your purchase of ImmunityBio securities during the class period.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Tattooed Chef Securities Settlement
Tattooed Chef, Inc. faced a securities lawsuit alleging that purchasers of the company's common stock were damaged. The defendant has agreed to settle all claims in the action for $4,750,000 in cash without admitting wrongdoing.
Estée Lauder Securities Settlement
Estée Lauder is settling securities litigation relating to alleged damages to investors who purchased or acquired publicly traded common stock of The Estée Lauder Companies Inc. during the class period. The defendant has not admitted wrongdoing in this settlement.
E-Commerce China Dangdang Securities Settlement
E-Commerce China Dangdang, Inc. was involved in a take-private transaction (merger) that closed on September 20, 2016. Shareholders who held American Depositary Shares during the Class Period claim they were harmed by undisclosed information related to the Company's take-private transaction. The defendant has agreed to settle these securities claims without admitting wrongdoing.
Evolv Technologies Holdings Securities Settlement
Investors purchased publicly traded common stock of Evolv Technologies Holdings Inc. during a specific period and are entitled to compensation from a securities class action settlement. The page does not explicitly state what wrongdoing Evolv allegedly committed.